MCM
IART icon

Manchester Capital Management’s Integra LifeSciences IART Stock Holding History

Manchester Capital Management’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-48
Closed -$597 – 1350
2025
Q4 		$597 Buy
+48
New +$638 ﹤0.01% 1242

Other funds holding IART

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Manchester Capital Management's IART Position: Q1 2026 in Review

Manchester Capital Management sold out of Integra LifeSciences (IART) in Q1 2026, closing a stake of 48 shares — an estimated $597 sold.

Manchester Capital Management first reported a position in IART in Q4 2025 and held it in 1 quarter. The position peaked at $597 in Q4 2025. 201 funds tracked by Wall St. Rank hold IART as of Q1 2026.

  • Manchester Capital Management reported no remaining Integra LifeSciences position as of Q1 2026 after selling out during the quarter.
  • Manchester Capital Management sold 48 Integra LifeSciences shares in Q1 2026, an estimated $597.
  • Manchester Capital Management first reported a position in Integra LifeSciences in Q4 2025 and held it in 1 quarter.
  • Manchester Capital Management's Integra LifeSciences position peaked at $597 in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2026.

Based on Manchester Capital Management's 13F filing for Q1 2026, filed 11 May 2026.